Get to Know Dr. Erin Alexis Gillaspie
Thoracic surgeon Dr. Erin Gillaspie joined the Vanderbilt University Medical Center as an assistant professor in 2016, bringing the patient-comes-first philosophy that she absorbed during her fellowship at the heralded Mayo Clinic in Minnesota.
“Patients here get my full and undivided attention,” she said. “The needs of the patient come first, always.”
Gillaspie serves as head of the Thoracic Surgery Robotics Program at Vanderbilt and chair of the Surgery Undergraduate Medical Education Committee.
Her clinical focus revolves around lung cancer, esophageal cancer, mediastinal tumors and pleural mesothelioma. She also plays a role in the Lung Transplant program at Vanderbilt, the only program of its kind in Tennessee.
Gillaspie is the principal investigator for a mesothelioma clinical trial at Vanderbilt-Ingram Cancer Center studying the survival benefits of adding the immunotherapy drug durvalumab to standard chemotherapy, a combination with considerable promise.
Specialties of Dr. Erin Alexis Gillaspie
- Thoracic surgery
- Minimally invasive surgery
- Surgical oncology
- Lung cancer
- Lung transplantation
- Pleural mesothelioma
- Mediastinal tumors
- Metastatic pulmonary nodules
- Esophageal cancer
Dr. Erin Alexis Gillaspie’s Experience and Medical Education
- Vanderbilt University Medical Center
- Mayo Clinic, Rochester, Minnesota (Fellowship)
- Bassett Medical Center, Cooperstown, New York (Residency)
- Spartanburg Regional Medical Center, Spartanburg, South Carolina (Internship)
- University of Miami Miller School of Medicine (M.D.)
Awards and Certifications
- Board Certified in Surgery and Thoracic Surgery, American Board of Surgery
- Association for Academic Surgery Cardiothoracic Young Investigator Award
- Mayo Clinic: Above and Beyond for Patient Care Award
- Surgical Intern of the Year
Mesothelioma Clinical Trials Under Erin Alexis Gillaspie, M.D.
- A phase III clinical trial involving the use of durvalumab, an immunotherapy drug, in combination with standard chemotherapy for patients with unresectable pleural mesothelioma. The purpose is to determine whether the addition of durvalumab will improve overall survival.
Publications of Dr. Erin Alexis Gillaspie
- Wilfong, E.M. et al. (2022, January). Anti-tRNA synthetase syndrome interstitial lung disease: A single center experience. Respiratory Medicine.
- Gupta, I. et al. (2021, March). Epidemiologic Trends in Pleural Infection. A Nationwide Analysis. Annals of the American Thoracic Society.
- Gillaspie, E.A., Lim, K. & Nichols, F.C. (2018, February 1). Surgical Management of Chyloptysis. The Annals of Thoracic Surgery.
- Gillaspie, EA. & Wigle, D.A. (2016, August). Management of Stage IIIA (N2) Non-Small Cell Lung Cancer. Thoracic Surgery Clinics.
Thank you for your feedback. Would you like to speak with a Patient Advocate?